At the moment we welcome Gene Mack, President and CEO of Achieve Therapeutics.
With over 25 years of expertise spanning biochemistry, Wall Road evaluation, and biotech management, Gene brings deep experience in capital markets, technique, and drug growth. He joined Achieve in 2024 and stepped into the CEO function in early 2025.
Achieve Therapeutics is a clinical-stage biotech pioneering next-generation allosteric small molecule therapies. Utilizing its proprietary Magellan platform, which mixes 3D structural biology and physics-based modeling, the corporate is unlocking novel therapies for difficult issues. Their lead candidate is advancing towards Part 2 as a possible first-in-class disease-modifying remedy for Parkinson’s illness, with promising Part 1b information exhibiting biomarker enhancements and useful advantages.
On this episode, we’ll discover Gene’s journey, Achieve’s revolutionary technique, the Parkinson’s panorama, and the way forward for AI in biotech.
· 01:28 Meet Gene Mack
· 11:15 GAIN’s mission: illness modification over symptom reduction
· 17:07 Why current Parkinson’s therapies fall brief
· 22:39 Origins and evolution of the Magellan platform
· 26:16 How AI modifications drug discovery past simply velocity
· 28:13 Part 1b examine design and open-label extension outcomes
· 32:09 Partnership technique and path to Part 2
· 35:29 Recommendation for leaders in neurodegeneration
Involved in being a sponsor of an episode of our podcast? Uncover how one can become involved right here!
Keep up to date by subscribing to our publication
To dive deeper into the subject:
11:15
GAIN’s mission: illness modification over symptom reduction
17:07
Why current Parkinson’s therapies fall brief
22:39
Origins and evolution of the Magellan platform
26:16
How AI modifications drug discovery past simply velocity
28:13
Part 1b examine design and open-label extension outcomes
32:09
Partnership technique and path to Part 2
35:29
Recommendation for leaders in neurodegeneration
